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Hereditary paraganglioma syndrome has recently been shown to be caused by germline heterozygous mutations in
three (SDHB, SDHC, and SDHD) of the four genes that encode mitochondrial succinate dehydrogenase. Extra-
paraganglial component neoplasias have never been previously documented. In a population-based registry of
symptomatic presentations of phaeochromocytoma/paraganglioma comprising 352 registrants, among whom 16
unrelated registrants were SDHB mutation positive, one family with germline SDHB mutation c.847-50delTCTC
had two members with renal cell carcinoma (RCC), of solid histology, at ages 24 and 26 years. Both also had
paraganglioma. A registry of early-onset RCCs revealed a family comprising a son with clear-cell RCC and his
mother with a cardiac tumor, both with the germline SDHB R27X mutation. The cardiac tumor proved to be a
paraganglioma. All RCCs showed loss of the remaining wild-type allele. Our observations suggest that germline
SDHB mutations can predispose to early-onset kidney cancers in addition to paragangliomas and carry implications
for medical surveillance.
Hereditary neoplasia syndromes that include pheochro-
mocytomas or extra-adrenal pheochromocytomas (para-
gangliomas [PGLs]) included multiple-endocrine neopla-
sia type 2 (MEN 2 [MIM 171400]), von Hippel-Lindau
disease (VHL [MIM 193300]), and type 1 neuroﬁbroma-
tosis (MIM 162200) for several decades. Recently, germ-
line mutations in SDHD (MIM 602690), a nuclear gene
encoding the D subunit of the mitochondrial enzyme suc-
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cinate dehydrogenase (SDH), were described in families
with head and neck PGLs (Baysal et al. 2000). Subse-
quently, the tumor spectrum for germline mutations in
SDHD was expanded to include familial and apparently
sporadic pheochromocytomas (reviewed by Maher and
Eng [2002]). It is interesting that germline mutations in
genes encoding two other subunits of SDH (mitochondrial
complex II), SDHB (MIM 185470 and MIM 605373)
and SDHC (MIM 602413), were found to be associated
with heritable pheochromocytoma and/or PGL (Maher
and Eng 2002; Eng et al. 2003). No germline mutations
in SDHA (MIM 600857) have been found in pheochro-
mocytoma or PGL cases. Instead, homozygous SDHA
mutations result in congenital severe neurodegeneration
and seizures. In a population-based study, ∼25% of all
apparently sporadic (deﬁned as “without syndromic fea-
tures and family history”) clinical presentations of pheo-
chromocytoma were found to harbor occult germlinemu-
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tations in SDHB, SDHD, VHL (which results in VHL),
and RET (which results in MEN 2) (Neumann et al.
2002). Until now, it was believed that there were no other
extraparaganglial manifestations in those carrying SDH
mutations (Baysal 2002; Baysal et al. 2002; Maher and
Eng 2002; Eng et al. 2003).
Apart from SDH, germline heterozygous mutations in
only one other nuclear-encoded gene that codes for a mi-
tochondrial enzyme, FH-encoding fumarate hydratase
(fumarase [MIM 136850]), has been described in a seem-
ingly unrelated inherited cancer syndrome, hereditary
leiomyomatosis and renal cell carcinoma (HLRCC [MIM
605839]) (Tomlinson et al. 2002). Paralleling SDH, ho-
mozygous germline mutations in FH cause severe neuro-
degeneration (FH deﬁciency [MIM 606812]) (Eng et al.
2003). Therefore, because of the mitochondrial etiolo-
gies for both SDH-related heritable PGL and HLRCC,
we sought to determine the existence of PGL in a popu-
lation-based registry of renal cell carcinoma (RCC)
and the existence of RCC in a population-based reg-
istry of symptomatic presentations of PGL and ad-
renal pheochromocytomas.
Family 1 was ascertained in a computerized search of
the national Finnish Cancer Registry for RCC cases di-
agnosed at ages 15–34 years, followed by construction
of pedigree and documentation through patient records,
in accordance with the institutional review boards for
human subjects protection of the University of Helsinki
and The Ohio State University. This search revealed 244
unrelated patients with RCC. After pedigree expansion
and documentation, family 1 was ascertained. The index
patient received the diagnosis of RCC at age 28 years
(ﬁg. 1A). At the time of diagnosis, the tumor had already
widely metastasized, and a palliative nephrectomy was
performed. The resected kidney, encompassing the tu-
mor, weighed 2,915 g and measured 17 # 23 cm. His-
tologically, the tumor was a conventional (clear cell) car-
cinoma that showed a mixture of clear cells and cells with
granular-eosinophilic cytoplasm. The proband’s mother
(patient II-1) (ﬁg. 1A), at age 55 years, received a diag-
nosis of a malignant PGL of the heart growing from the
septum to the right ventricle. In her case, the tumor was
considered inoperable, and it eventually led to the demise
of the patient. The proband’s maternal uncles (patients
II-2 and II-4) had small-cell lung carcinoma, diagnosed
at age 55 years, and pancreatic carcinoma, diagnosed at
age 71 years, respectively (ﬁg. 1). No samples from in-
dividual II-4 were available for further analysis.
Germline genomic DNA from archived normal tissue
of the deceased index patient was examined for the
presence of constitutional mutations in SDHA, SDHB,
SDHC, and SDHD by direct semiautomated sequence
analysis, as described elsewhere (Neumann et al. 2002)
(primers for SDHA analysis available on request from
C.E. [eng.25@osu.edu]). A germline heterozygous trun-
cating mutation in SDHB, R27X, was found in the pro-
band (III-1), his mother (II-1), and his uncle (II-2). DNA
was then extracted from the proband’s RCC, his mother’s
cardiac PGL, and his uncle’s lung tumor. Direct sequenc-
ing revealed somatic loss of the remaining wild-type
SDHB allele in the proband’s renal tumor and in his
mother’s PGL (ﬁg. 1B) but not in his uncle’s lung car-
cinoma. The uncle smoked cigarettes for 140 years, and,
in the absence of loss of heterozygosity of the wild-type
allele, the lung cancer is probably unrelated to the SDHB
mutation.
Family 2 was ascertained from a population-based
registry of the Freiburg-Warsaw-Columbus Phaeochro-
mocytoma Study Group, which registers all clinical pres-
entations of pheochromocytomas in Germany and cen-
tral Poland, in accordance with the institutional review
boards of The Ohio State University, the University of
Freiburg, and the Institute of Cardiology, Warsaw (Neu-
mann et al. 2002) (ﬁg. 2A). In this registry, there are 352
unrelated registrants, and 16 (∼5%) have been found to
carry germline SDHB mutations (Neumann et al. 2002;
H. Neumann and C. Eng, unpublished observations).
Among those 16, two siblings (patients II-2 and II-1)
were found to have RCC with solid histology diagnosed
at ages 24 years and 26 years, respectively (ﬁg. 2A). Both
siblings also had PGL. It is interesting that patient II-1
received a diagnosis of RCC ﬁrst, before his PGL diag-
nosis. Direct sequencing of genomic DNA, extracted from
blood leukocytes, revealed a germline heterozygous
frameshift mutation in SDHB, c.847-50delTCTC. The
PGL from patient II-2 and both renal tumors showed
somatic loss of the remaining wild-type allele (ﬁg. 2B).
To determine whether SDH also plays a role in all
individuals with generic sporadic renal carcinoma, we
examined SDHA, SDHB, SDHC, and SDHD for germ-
line and somatic mutations in 60 sporadic RCCs (30
clear cell, 3 papillary, 2 granular cell, 1 mixed papillary/
clear cell, 1 mixed clear cell/solid histology, 9 oncocytic
papillary, and 14 oncocytoma) diagnosed at any age. No
germline or somatic mutations were found in these four
genes. Because the SDHB-related RCCs were diagnosed
at ages !30 years, we then examined for mutations in
these four genes in 35 tumors with clear cell histology
diagnosed at ages !50, but no mutations were found.
Our SDHB-mutation–positive carriers with RCCs are
particularly young (!30 years), and the common clear
cell histology does not predominate in these (or among
SDHB-related) RCCs. Thus, it would not be a surprise
to ﬁnd no mutations in our series of kidney carcinomas
for which the predominant age at onset is approxi-
mately in the 60s and for which clear cell histology
predominates.
To our knowledge, this is the ﬁrst time that a gene
encoding one subunit of the mitochondrial SDH com-
plex has been implicated in renal carcinogenesis and the
Figure 1 Family 1, with documented RCC, cardiac PGL, and the germline SDHB R27X mutation. A, Pedigree of family 1. Generation
numbers are represented by Roman numerals. Individual numbers are in Arabic numerals. The index patient (proband) is III-1, indicated by
the arrow. “Mut” indicates mutation-positive individuals. B, Sequencing chromatogram representing part of SDHB exon 2. The sequences
around codon 27 from a normal control is shown at the top (“Normal”). The germline of the proband showed a heterozygous R27X mutation
with a wild-type C and a mutant T (N8168). The tumor DNA shows loss of the wild-type C allele, leaving only the mutant T (T8168). The
proband’s mother’s germline (N8104) showed the heterozygous R27X mutation, whereas her tumor (T8104) showed loss of the remaining
wild-type allele. (Note that, although the right panel was obtained in reverse sequence, the reverse complement chromatogram, which represents
a computer-generated forward sequence, is shown for ease of viewing.)
Figure 2 Family 2, with documented PGL and RCC and germline heterozygous SDHB c.847-50delTCTC mutation. A, Pedigree of family
2. The mutation-positive individuals are indicated by “Mut.” The index patient is II-2 (5792), indicated by the arrow. B, Sequencing chro-
matogram in the region of nucleotides 845–855 of SDHB. The wild-type sequence from a normal control is in the top panel (“Normal”). The
bar below the TCTC denotes the region of deletion. The germline DNA from both the index patient and her brother showed the heterozygous
c.847-50delTCTC microdeletion mutation. Note that, because of the nature of the repeats, we cannot ascertain whether the microdeletion is
c.847-50delTCTC or c.848-51delCTCT. When the mutant allele is present heterozygously with the wild type (“5842 germline” and “5792
germline”), the reading frame is shifted at the point of microdeletion. When the wild-type allele is lost, as in all three tumors (“5842 RCC,”
“5792 RCC,” and “5792 PGL”), the mutant allele remains.
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ﬁrst time that extraparaganglial disease has been shown
to be part of the PGL syndromes characterized by SDH
mutations. SDH is a part of the Krebs tricarboxylic acid
cycle and the mitochondrial electron transport chain,
which are required for the energy metabolism of all cells
(reviewed by Eng et al. [2003]). Anchored by SDHC and
SDHD, the catalytic subunits of complex II, SDHA and
SDHB, convert succinate to fumarate in an energy-de-
pendent reaction and pass fumarate to the next enzyme
in the Krebs cycle, FH. It is interesting that germline FH
mutations are associated with HLRCC (Tomlinson et al.
2002). The RCCs in HLRCC typically have type II pap-
illary histology. Nonetheless, the renal cancers seen in our
families with the SDHB-positive mutation are of varied
histology, ranging from solid to clear cell and cells with
granular-eosinophilic cytoplasm. All these carcinomas
originate from epithelial cells of the proximal renal tu-
bule. Thus, it is etiologically interesting that a defect in
mitochondrial enzymes is involved in the pathogenesis
of these subhistologies of RCC. The mechanism leading
to neoplastic transformation after damage to the Krebs
cycle and mitochondrial electron transport is still far
from fully understood, but a hypothesis that these events
lead to a proliferative hypoxic signal or oxidative DNA
damage has been proposed (Jeffers et al. 1997; Eng et
al. 2003). Accumulation of reactive oxygen species could
result from dysfunction inmitochondrial energymetabo-
lism; results supporting this theory have been reported
(Jeffers et al. 1997; Eng et al. 2003). Another possible
and not mutually exclusive mechanism by which mito-
chondrial dysfunction may lead to neoplasia is through
the role of mitochondria in apoptosis (Eng et al. 2003).
Because RCCs are referred to as “oncocytic” (i.e., replete
with mitochondria), the role of SDH in RCC is plausible.
Other RCC-susceptibility genes do not encode mito-
chondrial enzymes. Although seemingly disparate, the
majority of (or perhaps all) heritable RCC syndromes
might involve the HIF-VEGF pathway. VHL, caused by
germline mutations in VHL, is characterized by clear cell
RCC, pheochromocytoma mainly of the adrenal medulla,
and hemangiomas of the CNS and retina (Latif et al.
1993; Clifford and Maher 2001; Maher and Eng 2002).
A genotype-phenotype correlation exists in regard to the
frequencies of RCC and pheochromocytoma in a particu-
lar family (Crossey et al. 1994; Chen et al. 1995). Trun-
cating germline mutations are associated with RCC,
whereas missense mutations are associated with pheo-
chromocytoma (Crossey et al. 1994; Chen et al. 1995).
TheVHL protein has several functions; for example, bind-
ing and shepherding one of the subunits of hypoxia-in-
ducible factor (HIF) toward ubiquitin-mediated proteoly-
sis in the presence of oxygen (Ohh et al. 2000; Clifford
and Maher 2001; Clifford et al. 2001). When VHL is
nonfunctional, HIF is upregulated. When mitochondrial
function is impaired (e.g., as a consequence of SDHB
mutations), severe energy deﬁcits occur and oxygen free
radicals are generated.Whenmitochondria sense the pres-
ence of oxygen free radicals (hypoxia), HIFs are activated
and are translocated to the nucleus to induce gene ex-
pression (Eng et al. 2003). Thus, it may be postulated
that both RCC and pheochromocytoma/PGL suscepti-
bility resulting from SDHB deﬁciency could be mecha-
nistically related to RCC and to pheochromocytoma sus-
ceptibility secondary to VHL dysfunction, via HIF (Eng
et al. 2003).
Tuberous sclerosis (TSC [MIM 191100]), associated
with germline mutations in TSC1 or TSC2, is character-
ized by renal angiomyolipomas and cysts; dermatologic
lesions, such as ash leaf patches and shagreen patches;
epilepsy; mental retardation; and hamartomas of the eye
(Kwiatkowski 2003). Multifocal RCCs have been re-
ported in several TSC cases (Sampson et al. 1995; Taka-
hashi et al. 2002). Recently, loss or dysfunction of Tsc2
in the Eker rat model was shown to result in upregulation
of Hif2-a in RCC (Liu et al. 2003). Familial papillary
RCC (MIM 164860) is a rare syndrome caused by germ-
line mutations in the MET proto-oncogene (Schmidt et
al. 1997). The ligand for MET, hepatocyte growth factor,
has been shown to upregulate HIF-1 activity (Tacchini et
al. 2001; Matteucci et al. 2003). Germline mutations in
HRPT2 have been recently associated with hyperpara-
thyroidism jaw tumor syndrome (MIM 145001), and
germline mutations in BHD, encoding folliculin, have
been associated with Birt-Hogg-Dube´ syndrome (MIM
135150); both of these diseases have RCC as component
tumors (Khoo et al. 2002; Nickerson et al. 2002). Al-
though the function of folliculin and HRPT2 has yet
to be elucidated, it would appear that the HIF-VEGF
pathway might be an important downstream common
pathway for renal neoplasia in many heritable RCC
syndromes.
The German-Polish Registry includes 16 unrelated pro-
bands with germline SDHB mutations and a total of 31
mutation carriers (Neumann et al. 2002; H. Neumann
andC. Eng, unpublished observations). Using theRegistry
to help estimate the frequency of RCC among SDHB
mutation–positive individuals, we approximate a 5%–
10% prevalence. Given the age distribution of SDHB car-
riers in the registry (mean age 30 years; 40% !20 years,
15% 140), this 5%–10% estimate might be slightly low.
In contrast, results of the Finnish Registry search suggest
a prevalence of !1% of all early-onset RCC. If our ob-
servations can be independently conﬁrmed, then indi-
viduals and families with germline SDHB mutations
should also undergo routine clinical surveillance for the
development of early-onset renal carcinomas. Con-
versely, if a patient with RCC were found to harbor the
germline SDHB mutation, then annual surveillance for
pheochromocytoma and PGL should be considered. On
the basis of our observations, very early–onset RCC with
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unusual histology (e.g., solid) should alert a clinician to
take an extended family history. Like most heritable
RCCs, (e.g., VHL-related [Neumann et al. 1998]), it is
possible that SDHB-related RCC might also have a better
prognosis. Of the three patients studied in this report, one
is still alive after long follow-up; one has died ofmetastatic
disease, but not until 6 years after diagnosis; and the third
died of metastatic disease 1 year and 4 mo after initial
diagnosis. Thus, longer follow-up and study of other cases
are required to investigate this aspect of the disease.
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